News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics enter into collaboration and option agreement to develop oligonucleotide therapies for rare renal indications. Combine expertise in rare diseases and biologics -
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
Secarna Pharmaceuticals partners with Scenic Biotech to develop disease-modifying oligonucleotide therapy against novel drug target, leveraging expertise and synergies for new treatments -
